Description
Description
This page contains brief details about the drug brentuximab vedotin, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
The Brentuximab vedotin is medically approved for the treatment of Hodgkin lymphoma, cutaneous T-cell lymphoma and systemic Anaplastic Large Cell Lymphoma.
Mechanism of Action of Brentuximab Vedotin
Brentuximab vedotin consists of an antibody targeting CD30, a protein found on the surface of cancer cells, and a chemotherapy drug attached to the antibody. The antibody delivers the chemotherapy directly to the cancer cells, minimizing damage to healthy cells.
Uses of Brentuximab Vedotin
Brentuximab vedotin is used to treat various cancers, including classical Hodgkin lymphoma (both newly diagnosed and relapsed), systemic anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma, cutaneous T-cell lymphoma, and CD30-expressing mycosis fungoides, all in combination with other therapies.
Brentuximab Vedotin Dosage available
Brentuximab vedotin can be administered only as an intravenous injection into a vein by your physician in a hospital setting. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition.
